Article
Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.
Endocrine-related cancer - 1 Dec 2013
Rudolph Anja, Hein Rebecca, Lindström Sara, Beckmann Lars, Behrens Sabine, Liu Jianjun, Aschard Hugues, Bolla Manjeet K, Wang Jean, Truong Thérèse, Cordina-Duverger Emilie, Menegaux Florence, Brüning Thomas, Harth Volker, Severi Gianluca, Baglietto Laura, Southey Melissa, Chanock Stephen J, Lissowska Jolanta, Figueroa Jonine D, Eriksson Mikael, Humpreys Keith, Darabi Hatef, Olson Janet E, Stevens Kristen N, Vachon Celine M, Knight Julia A, Glendon Gord, Mulligan Anna Marie, Ashworth Alan, Orr Nicholas, Schoemaker Minouk, Webb Penny M, Guénel Pascal, Brauch Hiltrud, Giles Graham, García-Closas Montserrat, Czene Kamila, Chenevix-Trench Georgia, Couch Fergus J, Andrulis Irene L, Swerdlow Anthony, Hunter David J, Flesch-Janys Dieter, Easton Douglas F, Hall Per, Nevanlinna Heli, Kraft Peter, Chang-Claude Jenny
Abstract excerpt
Women using menopausal hormone therapy (MHT) are at increased risk of developing breast cancer (BC). To detect genetic modifiers of the association between current use of MHT and BC risk, we conducted a meta-analysis of four genome-wide case-only studies followed by replication in 11 case-control studies. We used a case-only design to assess interactions between single-nucleotide polymorphisms (SNPs) and current...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.